SRR1516047
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.380
- ANGIOGENESIS+0.290
- MYC_TARGETS_V1+0.230
- PANCREAS_BETA_CELLS+0.220
- SPERMATOGENESIS+0.220
- MITOTIC_SPINDLE+0.210
- MYOGENESIS+0.190
- HEDGEHOG_SIGNALING+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- P53_PATHWAY-0.360
- WNT_BETA_CATENIN_SIGNALING-0.300
- INTERFERON_GAMMA_RESPONSE-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- PI3K_AKT_MTOR_SIGNALING-0.160
- ESTROGEN_RESPONSE_EARLY-0.150
- GLYCOLYSIS-0.130
- COMPLEMENT-0.120
- HEME_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 65460 | EPN | Supratentorial EPN | 0.745 |
| 2 | SRR6013587 | — | cohortA3 | 0.742 |
| 3 | DRR168514 | — | — | 0.715 |
| 4 | c45adda2-fffe-4add-8148-01ecf35dd855 | — | — | 0.699 |
| 5 | TCGA-CV-7102-01A-11R-2016-07 | — | — | 0.699 |
| 6 | TCGA-OR-A5KY-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.698 |
| 7 | DRR168595 | — | — | 0.686 |
| 8 | MNG2 | — | — | 0.675 |
| 9 | TCGA-22-4593-01A-21R-1820-07 | — | cohortSQ1 | 0.666 |
| 10 | ULC0571T_S29 | — | cohortSQ1 | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |